{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:13:51Z","timestamp":1792653231554,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lysophosphatidic acid (LPA) is a pleiotropic lipid messenger that addresses at least six specific G-protein coupled receptors. Accumulating evidence indicates a significant involvement of LPA in immune cell regulation as well as Schwann cell physiology, with potential relevance for the pathophysiology of peripheral neuroinflammation. However, the role of LPA signaling in inflammatory neuropathies has remained completely undefined. Given the broad expression of LPA receptors on both Schwann cells and cells of the innate and adaptive immune system, we hypothesized that inhibition of LPA signaling may ameliorate the course of disease in experimental autoimmune neuritis (EAN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We induced active EAN by inoculation of myelin protein 2 peptide (P2<jats:sub>55\u201378<\/jats:sub>) in female Lewis rats. Animals received the orally available LPA receptor antagonist AM095, specifically targeting the LPA<jats:sub>1<\/jats:sub> receptor subtype. AM095 was administered daily via oral gavage in a therapeutic regimen from 10 until 28\u00a0days post-immunization (dpi). Analyses were based on clinical testing, hemogram profiles, immunohistochemistry and morphometric assessment of myelination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Lewis rats treated with AM095 displayed a significant improvement in clinical scores, most notably during the remission phase. Cellular infiltration of sciatic nerve was only discretely affected by AM095. Hemogram profiles indicated no impact on circulating leukocytes. However, sciatic nerve immunohistochemistry revealed a reduction in the number of Schwann cells expressing the dedifferentiation marker Sox2 paralleled by a corresponding increase in differentiating Sox10-positive Schwann cells. In line with this, morphometric analysis of sciatic nerve semi-thin sections identified a significant increase in large-caliber myelinated axons at 28 dpi. Myelin thickness was unaffected by AM095.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Thus, LPA<jats:sub>1<\/jats:sub> signaling may present a novel therapeutic target for the treatment of inflammatory neuropathies, potentially affecting regenerative responses in the peripheral nerve by modulating Schwann cell differentiation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-021-02350-5","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T11:14:19Z","timestamp":1639739659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["LPA1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis"],"prefix":"10.1186","volume":"18","author":[{"given":"Fabian","family":"Szepanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Winkelhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca D.","family":"Steubing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Mausberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"2350_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes RA, Cornblath DR. Guillain\u2013Barre syndrome. Lancet. 2005;366:1653\u201366.","journal-title":"Lancet"},{"key":"2350_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"H Koller","year":"2005","unstructured":"Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1343\u201356.","journal-title":"N Engl J Med"},{"key":"2350_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ncpneuro0452","volume":"3","author":"G Meyer zu Horste","year":"2007","unstructured":"Meyer zu Horste G, Hartung HP, Kieseier BC. From bench to bedside\u2013experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol. 2007;3:198\u2013211.","journal-title":"Nat Clin Pract Neurol"},{"key":"2350_CR4","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1212\/WNL.59.12_suppl_6.S7","volume":"59","author":"BC Kieseier","year":"2002","unstructured":"Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002;59:S7-12.","journal-title":"Neurology"},{"key":"2350_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","volume":"4","author":"BC Kieseier","year":"2018","unstructured":"Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4:31.","journal-title":"Nat Rev Dis Primers"},{"key":"2350_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/glia.22899","volume":"64","author":"R Martini","year":"2016","unstructured":"Martini R, Willison H. Neuroinflammation in the peripheral nerve: cause, modulator, or bystander in peripheral neuropathies? Glia. 2016;64:475\u201386.","journal-title":"Glia"},{"key":"2350_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nature09614","volume":"468","author":"KA Nave","year":"2010","unstructured":"Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468:244\u201352.","journal-title":"Nature"},{"key":"2350_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nbd.2013.03.005","volume":"55","author":"E Ydens","year":"2013","unstructured":"Ydens E, Lornet G, Smits V, Goethals S, Timmerman V, Janssens S. The neuroinflammatory role of Schwann cells in disease. Neurobiol Dis. 2013;55:95\u2013103.","journal-title":"Neurobiol Dis"},{"key":"2350_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mus.20893","volume":"37","author":"G Meyer zu Horste","year":"2008","unstructured":"Meyer zu Horste G, Hu W, Hartung HP, Lehmann HC, Kieseier BC. The immunocompetence of Schwann cells. Muscle Nerve. 2008;37:3\u201313.","journal-title":"Muscle Nerve"},{"key":"2350_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.nbd.2009.11.006","volume":"37","author":"G Meyer zu Horste","year":"2010","unstructured":"Meyer zu Horste G, Heidenreich H, Mausberg AK, Lehmann HC, ten Asbroek AL, Saavedra JT, Baas F, Hartung HP, Wiendl H, Kieseier BC. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation. Neurobiol Dis. 2010;37:483\u201390.","journal-title":"Neurobiol Dis"},{"key":"2350_CR11","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1002\/glia.23200","volume":"65","author":"SY Jang","year":"2017","unstructured":"Jang SY, Yoon BA, Shin YK, Yun SH, Jo YR, Choi YY, Ahn M, Shin T, Park JI, Kim JK, Park HT. Schwann cell dedifferentiation-associated demyelination leads to exocytotic myelin clearance in inflammatory segmental demyelination. Glia. 2017;65:1848\u201362.","journal-title":"Glia"},{"key":"2350_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2011.00360.x","volume":"16","author":"EJ Hutton","year":"2011","unstructured":"Hutton EJ, Carty L, Laura M, Houlden H, Lunn MP, Brandner S, Mirsky R, Jessen K, Reilly MM. c-Jun expression in human neuropathies: a pilot study. J Peripher Nerv Syst. 2011;16:295\u2013303.","journal-title":"J Peripher Nerv Syst"},{"key":"2350_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1194\/jlr.R046458","volume":"55","author":"YC Yung","year":"2014","unstructured":"Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192\u2013214.","journal-title":"J Lipid Res"},{"key":"2350_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuropharm.2016.04.002","volume":"113","author":"M Velasco","year":"2017","unstructured":"Velasco M, O\u2019Sullivan C, Sheridan GK. Lysophosphatidic acid receptors (LPARs): potential targets for the treatment of neuropathic pain. Neuropharmacology. 2017;113:608\u201317.","journal-title":"Neuropharmacology"},{"key":"2350_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.neuron.2015.01.009","volume":"85","author":"YC Yung","year":"2015","unstructured":"Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling in the nervous system. Neuron. 2015;85:669\u201382.","journal-title":"Neuron"},{"key":"2350_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nm1060","volume":"10","author":"M Inoue","year":"2004","unstructured":"Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10:712\u20138.","journal-title":"Nat Med"},{"key":"2350_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neulet.2017.10.023","volume":"662","author":"F Szepanowski","year":"2018","unstructured":"Szepanowski F, Szepanowski LP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M. Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA1 signaling. Neurosci Lett. 2018;662:136\u201341.","journal-title":"Neurosci Lett"},{"key":"2350_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jphs.2016.07.010","volume":"132","author":"R Tsukahara","year":"2016","unstructured":"Tsukahara R, Ueda H. Myelin-related gene silencing mediated by LPA1 - Rho\/ROCK signaling is correlated to acetylation of NFkappaB in S16 Schwann cells. J Pharmacol Sci. 2016;132:162\u20135.","journal-title":"J Pharmacol Sci"},{"key":"2350_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-016-0701-9","volume":"13","author":"I Plastira","year":"2016","unstructured":"Plastira I, Bernhart E, Goeritzer M, Reicher H, Kumble VB, Kogelnik N, Wintersperger A, Hammer A, Schlager S, Jandl K, et al. 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype. J Neuroinflammation. 2016;13:205.","journal-title":"J Neuroinflammation"},{"key":"2350_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12974-018-1259-5","volume":"15","author":"AK Mausberg","year":"2018","unstructured":"Mausberg AK, Szepanowski F, Odoardi F, Flugel A, Kleinschnitz C, Stettner M, Kieseier BC. Trapped in the epineurium: early entry into the endoneurium is restricted to neuritogenic T cells in experimental autoimmune neuritis. J Neuroinflammation. 2018;15:217.","journal-title":"J Neuroinflammation"},{"key":"2350_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1124\/jpet.110.175901","volume":"336","author":"JS Swaney","year":"2011","unstructured":"Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011;336:693\u2013700.","journal-title":"J Pharmacol Exp Ther"},{"key":"2350_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12974-016-0612-9","volume":"13","author":"F Szepanowski","year":"2016","unstructured":"Szepanowski F, Derksen A, Steiner I, Meyer Zu Horste G, Daldrup T, Hartung HP, Kieseier BC. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. J Neuroinflammation. 2016;13:143.","journal-title":"J Neuroinflammation"},{"key":"2350_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00401-017-1676-z","volume":"133","author":"F Szepanowski","year":"2017","unstructured":"Szepanowski F, Donaldson DM, Hartung HP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M. Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2\/HO-1 signaling pathway. Acta Neuropathol. 2017;133:489\u201391.","journal-title":"Acta Neuropathol"},{"key":"2350_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/glia.21173","volume":"59","author":"M Bremer","year":"2011","unstructured":"Bremer M, Frob F, Kichko T, Reeh P, Tamm ER, Suter U, Wegner M. Sox10 is required for Schwann-cell homeostasis and myelin maintenance in the adult peripheral nerve. Glia. 2011;59:1022\u201332.","journal-title":"Glia"},{"key":"2350_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1471-4159.2009.06498.x","volume":"112","author":"S Reiprich","year":"2010","unstructured":"Reiprich S, Kriesch J, Schreiner S, Wegner M. Activation of Krox20 gene expression by Sox10 in myelinating Schwann cells. J Neurochem. 2010;112:744\u201354.","journal-title":"J Neurochem"},{"key":"2350_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1083\/jcb.200912142","volume":"189","author":"M Finzsch","year":"2010","unstructured":"Finzsch M, Schreiner S, Kichko T, Reeh P, Tamm ER, Bosl MR, Meijer D, Wegner M. Sox10 is required for Schwann cell identity and progression beyond the immature Schwann cell stage. J Cell Biol. 2010;189:701\u201312.","journal-title":"J Cell Biol"},{"key":"2350_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200803013","volume":"181","author":"DB Parkinson","year":"2008","unstructured":"Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon LA, Woodhoo A, Lloyd AC, Feltri ML, Wrabetz L, Behrens A, Mirsky R, Jessen KR. c-Jun is a negative regulator of myelination. J Cell Biol. 2008;181:625\u201337.","journal-title":"J Cell Biol"},{"key":"2350_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.neuron.2012.06.021","volume":"75","author":"PJ Arthur-Farraj","year":"2012","unstructured":"Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, Woodhoo A, Jenkins B, Rahman M, Turmaine M, et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron. 2012;75:633\u201347.","journal-title":"Neuron"},{"key":"2350_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cell.2010.08.039","volume":"143","author":"S Parrinello","year":"2010","unstructured":"Parrinello S, Napoli I, Ribeiro S, Wingfield Digby P, Fedorova M, Parkinson DB, Doddrell RD, Nakayama M, Adams RH, Lloyd AC. EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting. Cell. 2010;143:145\u201355.","journal-title":"Cell"},{"key":"2350_CR30","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1073\/pnas.0407836102","volume":"102","author":"N Le","year":"2005","unstructured":"Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J. Analysis of congenital hypomyelinating Egr2Lo\/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci USA. 2005;102:2596\u2013601.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2350_CR31","first-page":"3114","volume":"144","author":"SL Roberts","year":"2017","unstructured":"Roberts SL, Dun XP, Doddrell RDS, Mindos T, Drake LK, Onaitis MW, Florio F, Quattrini A, Lloyd AC, D\u2019Antonio M, Parkinson DB. Sox2 expression in Schwann cells inhibits myelination in vivo and induces influx of macrophages to the nerve. Development. 2017;144:3114\u201325.","journal-title":"Development"},{"key":"2350_CR32","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1113\/JP270874","volume":"594","author":"KR Jessen","year":"2016","unstructured":"Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves. J Physiol. 2016;594:3521\u201331.","journal-title":"J Physiol"},{"key":"2350_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1742-2094-11-63","volume":"11","author":"M Stettner","year":"2014","unstructured":"Stettner M, Lohmann B, Wolffram K, Weinberger JP, Dehmel T, Hartung HP, Mausberg AK, Kieseier BC. Interleukin-17 impedes Schwann cell-mediated myelination. J Neuroinflammation. 2014;11:63.","journal-title":"J Neuroinflammation"},{"key":"2350_CR34","doi-asserted-by":"publisher","first-page":"9173090","DOI":"10.1155\/2017\/9173090","volume":"2017","author":"SA Valdes-Rives","year":"2017","unstructured":"Valdes-Rives SA, Gonzalez-Arenas A. Autotaxin-lysophosphatidic acid: from inflammation to cancer development. Mediators Inflamm. 2017;2017:9173090.","journal-title":"Mediators Inflamm"},{"key":"2350_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nn.2780","volume":"14","author":"Y Chen","year":"2011","unstructured":"Chen Y, Wang H, Yoon SO, Xu X, Hottiger MO, Svaren J, Nave KA, Kim HA, Olson EN, Lu QR. HDAC-mediated deacetylation of NF-kappaB is critical for Schwann cell myelination. Nat Neurosci. 2011;14:437\u201341.","journal-title":"Nat Neurosci"},{"key":"2350_CR36","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.4049\/jimmunol.166.4.2317","volume":"166","author":"Y Zheng","year":"2001","unstructured":"Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol. 2001;166:2317\u201322.","journal-title":"J Immunol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02350-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T11:14:42Z","timestamp":1639739682000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02350-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02350-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by local authorities (Landesamt f\u00fcr Natur-, Umwelt- und Verbraucherschutz Nordrhein-Westfalen, Germany).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FS, MW, RDS and AKM and CK have nothing to disclose. MS served on the scientific advisory boards and\/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec; Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}